The FDA has reported 392 adverse events with compounded semaglutide and 215 with compounded tirzepatide, including multiple hospitalisations from dosing errors
Typically, Semaglutide GLP-1 injections are recommended for individuals with a BMI of 30 or higher, or 27 or higher with weight-related health conditions
In IFALD patients, the median (IQR) values for GGT, ALP, ALT, AST, and Bilirubin were 254U/L(132-312), 233U/L(188.5-365), 54U/L(30.5-113.5), 44U/L(31.5-68.5), and 7umol/L(5.5-16) respectively
In other words, your body already makes its own version of these medications naturally
Severe diarrhea, defined as more than six loose stools per day or diarrhea that significantly interferes with daily activities, requires medical assessment
This strategy allowed insurers that didnt cover weight loss products to include the diabetes-indicated version on their drug formularies, while excluding the weight loss version